- Home
- HYI vs CDXS Comparison
HYI vs CDXS Comparison
Compare HYI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- CDXS
- Stock Information
- Founded
- HYI 2010
- CDXS 2002
- Country
- HYI United States
- CDXS United States
- Employees
- HYI N/A
- CDXS N/A
- Industry
- HYI Investment Managers
- CDXS Major Chemicals
- Sector
- HYI Finance
- CDXS Industrials
- Exchange
- HYI Nasdaq
- CDXS Nasdaq
- Market Cap
- HYI 279.2M
- CDXS 332.0M
- IPO Year
- HYI N/A
- CDXS 2010
- Fundamental
- Price
- HYI $11.98
- CDXS $5.28
- Analyst Decision
- HYI
- CDXS Buy
- Analyst Count
- HYI 0
- CDXS 2
- Target Price
- HYI N/A
- CDXS $11.00
- AVG Volume (30 Days)
- HYI 50.6K
- CDXS 875.4K
- Earning Date
- HYI 01-01-0001
- CDXS 10-31-2024
- Dividend Yield
- HYI 9.59%
- CDXS N/A
- EPS Growth
- HYI N/A
- CDXS N/A
- EPS
- HYI N/A
- CDXS N/A
- Revenue
- HYI N/A
- CDXS $64,446,000.00
- Revenue This Year
- HYI N/A
- CDXS N/A
- Revenue Next Year
- HYI N/A
- CDXS $2.02
- P/E Ratio
- HYI N/A
- CDXS N/A
- Revenue Growth
- HYI N/A
- CDXS N/A
- 52 Week Low
- HYI $10.99
- CDXS $2.53
- 52 Week High
- HYI $12.24
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- HYI 40.56
- CDXS 59.97
- Support Level
- HYI $11.95
- CDXS $5.42
- Resistance Level
- HYI $12.25
- CDXS $6.01
- Average True Range (ATR)
- HYI 0.09
- CDXS 0.39
- MACD
- HYI -0.02
- CDXS -0.05
- Stochastic Oscillator
- HYI 12.91
- CDXS 46.67
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.